Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This guideline outlines therapies for hidradenitis suppurativa/acne inversa, noting that oral tetracyclines, clindamycin, and surgical options are important for treatment, with adalimumab, secukinumab, and bimekizumab also approved.

This review discusses the potential of biologics for treating various skin disorders, highlighting positive outcomes in conditions like pityriasis rubra pilaris and lupus, while noting mixed efficacy in others like alopecia areata; it reports no new clinical results.

This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.

In this case report, a 64-year-old woman developed alopecia areata after starting the IL-17A inhibitor secukinumab for psoriasis, highlighting a potential rare side effect of this treatment, with only three similar cases reported in the literature.

This study reviewed clinical trials and reports on cytokine-targeting biologics for alopecia areata, finding Dupilumab and Ustekinumab showed strong efficacy, while other biologics had limited success or worsened the condition. Further research is needed to optimize biologic therapies for AA.

This case report describes a female patient with ankylosing spondylitis who developed generalized pustular psoriasis after adalimumab therapy, and whose condition improved following treatment with secukinumab and acitretin.

This study reviews current treatments for alopecia areata, highlighting that despite various options like corticosteroids and immunosuppressives, their limited efficacy and potential side effects are challenges, while targeting specific cytokines has shown promise except with TNF inhibitors, which may worsen the condition.

This research highlights advancements in understanding and treating psoriasis, finding that targeted therapies like IL-17 and IL-23 inhibitors show promise, but challenges such as adverse events, treatment resistance, and the need for personalized approaches remain.

Secukinumab reduces immune activity in hidradenitis suppurativa skin.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.

In a preclinical mouse model, this study found that early treatment with the selective SYK inhibitor entospletinib significantly improved survival rates and clinical outcomes for graft-versus-host disease after hematopoietic stem cell transplantation compared to placebo.

This review highlights the promising clinical outcomes of sacituzumab tirumotecan (sac-TMT), an antibody-drug conjugate for breast cancer that targets TROP2, demonstrating improved response rates and progression-free survival, with manageable safety concerns including primarily mild-to-moderate nausea and alopecia.

This review discusses recent advances and ongoing clinical trials in novel therapeutics for alopecia areata, despite the lack of current FDA-approved treatments for severe cases, and reports no new results.

This review discusses immune pathways involved in alopecia areata and explores emerging, more targeted therapeutic strategies, noting their potential for better safety and effectiveness compared to traditional immune suppressants.

This review discusses the complexities of managing adolescent psoriasis amidst challenges like identity formation and parent-adolescent dynamics, and proposes updated management strategies for 21st-century adolescents, but reports no new clinical results.

This review explores the inflammatory pathogenesis and clinical presentation of hidradenitis suppurativa, highlighting the complexity of treatment and the impact on patients' quality of life, while also examining emerging therapeutic options.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

TAK-279 effectively reduces psoriasis symptoms and is safe.

This study reports that sacituzumab govitecan achieved a 33.3% overall response rate in patients with metastatic triple-negative breast cancer who had prior treatments, with a median response duration of 7.7 months.

This review highlights the potential of Sacituzumab Tirumotecan, an antibody-drug conjugate, in treating gynecologic cancers, with ongoing Phase III trials indicating a manageable safety profile and future results expected to shed light on its effectiveness in improving survival and response rates.

This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.

Tofacitinib might be used to treat hair loss.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This case report describes the first successful use of telitacicept in treating a patient with systemic lupus erythematosus and a history of papillary thyroid carcinoma, suggesting its potential as a therapeutic option for such conditions.